Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
Conference Material
|Slide Presentation
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|Abstract
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. The efficacy of treatment with such reg...
The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. The efficacy of treatment with such reg...
Journal Article
|Research
2014-12-21 • Public Health Action
2014-12-21 • Public Health Action
SETTING
Belarus (Eastern Europe) is facing an epidemic of multidrug-resistant tuberculosis (MDR-TB). In 2012, rapid molecular diagnostics were prioritised for sputum smear-positive p...
Belarus (Eastern Europe) is facing an epidemic of multidrug-resistant tuberculosis (MDR-TB). In 2012, rapid molecular diagnostics were prioritised for sputum smear-positive p...
Journal Article
|Research
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTINGS
Tuberculosis (TB) health facilities in the Gomel Region, Republic of Belarus-settings with a high burden of multidrug-resistant TB (MDR-TB) and human immunodeficiency virus ...
Tuberculosis (TB) health facilities in the Gomel Region, Republic of Belarus-settings with a high burden of multidrug-resistant TB (MDR-TB) and human immunodeficiency virus ...
Journal Article
|Research
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING
Tuberculosis (TB), including drug-resistant TB, is a serious problem in Belarus.
OBJECTIVES
To determine the prevalence of TB among health care workers (HCWs) al...
Tuberculosis (TB), including drug-resistant TB, is a serious problem in Belarus.
OBJECTIVES
To determine the prevalence of TB among health care workers (HCWs) al...